Treatment Options for Male Erectile Dysfunction: A Systematic Review of Published211 Studies of Effectiveness. Technology Assessment Program

摘要

This report was written in response to a request to Veteran's Administration's211u001e(VA's) Technology Recommendations Panel (TRP) regarding treatment options for 211u001emale erectile dysfunction (ED). The TRP, a national committee, is 'responsible 211u001efor the evaluation of health care technologies and for preparing recommendations 211u001eregarding the use of such technologies' (TRP Charter, unpublished, 1997). The 211u001eHealth Services Research and Development Service, Management Decision and 211u001eResearch Center Technology Assessment Program commissioned the review on behalf 211u001eof the TRP. The intent of this report is to update and expand information from 211u001ethe 1996 American Urological Association Clinical Guidelines Panel on Erectile 211u001eDysfunction: Summary Report on the Treatment of Organic Erectile Dysfunction: 211u001eSummary Report on the Treatment of Organic Erectile Dysfunction. The current 211u001ereport relies primarily on results from randomized controlled trials of treatment 211u001efor ED published from January 1995-January 1999. It also includes results from 211u001eadditional sources including patient preference studies, post marketing reports, 211u001eproduct inserts and FDA announcements. It focuses on new FDA-approved therapies 211u001efor ED of greatest clinical and resource significance to the VA, i.e. oral 211u001esildenafil (Viagra); intraurethral alprostadil (MUSE); and intracavernous 211u001einjections of alprostadil (Caverject).